middle.news

How Aroa Biosurgery’s Record Myriad Sales Signal a Breakout Year Ahead

9:07am on Thursday 16th of October, 2025 AEDT Healthcare
Read Story

How Aroa Biosurgery’s Record Myriad Sales Signal a Breakout Year Ahead

9:07am on Thursday 16th of October, 2025 AEDT
Key Points
  • Operating cash flow of NZ$2.1 million for the quarter
  • Record quarterly sales of NZ$10.2 million for Myriad product family
  • Cash balance increased to NZ$23.4 million, remaining debt-free
  • FY26 revenue guidance reaffirmed at NZ$92-100 million with EBITDA of NZ$5-8 million
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about AROA BIOSURGERY (ASX:ARX)
OPEN ARTICLE